We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Metformin Plus Irinotecan for Refractory Colorectal Cancer

This study is currently recruiting participants.
Verified June 2017 by Barretos Cancer Hospital
Sponsor:
ClinicalTrials.gov Identifier:
NCT01930864
First Posted: August 29, 2013
Last Update Posted: June 22, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
University of Campinas, Brazil
AC Camargo Cancer Center
Information provided by (Responsible Party):
Barretos Cancer Hospital
  Purpose
MetIri seeks to identify if metformin combined to irinotecan can improve tumor control.

Condition Intervention Phase
Colorectal Neoplasms Adenocarcinoma Drug: metformin Drug: irinotecan Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of Metformin Combined to Irinotecan for Refractory Metastatic or Recurrent Colorectal Cancer

Resource links provided by NLM:


Further study details as provided by Barretos Cancer Hospital:

Primary Outcome Measures:
  • Non-Progression at week 12th of treatment [ Time Frame: 12th week ]
    Non-Progression at week 12th of treatment


Secondary Outcome Measures:
  • Progression-free survival [ Time Frame: 12th week ]
    Progression-free survival

  • Overall Survival [ Time Frame: 12th week ]
    Overall Survival

  • Quality of life [ Time Frame: 12th week ]
    Measured by EORTC QLQ C30

  • Safety [ Time Frame: 12th week ]
    Assessment of toxicity according to CTC 4.0


Estimated Enrollment: 41
Actual Study Start Date: September 1, 2015
Estimated Study Completion Date: December 1, 2020
Estimated Primary Completion Date: December 1, 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: metfomin + irinotecan
Irinotecan 350mg/m² q21d + metformin up to 2500mg/d until disease progression, prohibitive toxicity or consent withdrawal
Drug: metformin
metformin up to 2500mg/d
Drug: irinotecan
Irinotecan 350 mg/m² IV q21d

Detailed Description:
MetIri is a two-stage single arm Phase II assessing the role of combination of metformin to irinotecan for colorectal cancer patients already treat with oxaliplatin, fluoropyrimidine, irinotecan and an anti-EGFr antibody if KRAS wild-type.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years or older
  • Biopsy-proven colorectal adenocarcinoma
  • Ineligibility for curative intent therapy, e.g., surgery or radiation
  • Disease progression after oxaliplatin (either adjuvant or palliative), fluoropyrimidine (either adjuvant or palliative), irinotecan, and if Kras wild type a anti-EGFR therapy
  • Assessable disease according to RECIST v1.1

Exclusion Criteria:

  • known hypersensitivity to metformin or irinotecan
  • Uncontrolled Central nervous system metastasis
  • Acute or chronic severe infection
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01930864


Contacts
Contact: Joao Paulo SN Lima, MD 551733216600 ext 7128 joao.lima@accamargo.org.br
Contact: Arinilda C Bragagnoli, MD 551733216600 ext 6829 aryscampos@yahoo.com.br

Locations
Brazil
Barretos Cancer Hospital Recruiting
Barretos, SP, Brazil, 14784-400
Contact: Joao Paulo SN Lima, MD    551733216600 ext 6829    joao.lima@accamargo.org.br   
Contact: Arinilda C Bragagnoli, MD    551733216600 ext 6829    aryscampos@yahoo.com.br   
Principal Investigator: Arinilda C Bragagnoli, MD         
State University of Campinas Not yet recruiting
Campinas, São Paulo, Brazil, 1300000
Contact: Lígia T Macedo, MD       ligaimed@gmail.com   
Principal Investigator: Ligia T Macedo, MD         
Sponsors and Collaborators
Barretos Cancer Hospital
University of Campinas, Brazil
AC Camargo Cancer Center
Investigators
Principal Investigator: Joao Paulo SN Lima, MD, PhD AC Camargo Cancer Center
  More Information

Publications:
Responsible Party: Barretos Cancer Hospital
ClinicalTrials.gov Identifier: NCT01930864     History of Changes
Other Study ID Numbers: MetIri
First Submitted: August 26, 2013
First Posted: August 29, 2013
Last Update Posted: June 22, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Upon data collection, the info will be put on a online database

Keywords provided by Barretos Cancer Hospital:
metformin
colorectal cancer
chemotherapy

Additional relevant MeSH terms:
Colorectal Neoplasms
Adenocarcinoma
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Metformin
Irinotecan
Camptothecin
Hypoglycemic Agents
Physiological Effects of Drugs
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action